Skip to main content

Mintezol Disease Interactions

There are 3 disease interactions with Mintezol (thiabendazole).

Moderate

Anthelmintics (applies to Mintezol) supportive therapy

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Dehydration, Malnourished, Anemia

Patients with anemia, dehydration, or malnutrition should receive supportive therapy for these complicating conditions prior to initiation of certain anthelmintic therapy.

References

  1. (2001) "Product Information. Mintezol (thiabendazole)." Merck & Co., Inc
  2. (2001) "Product Information. Antiminth (pyrantel)." Pfizer U.S. Pharmaceuticals Group
  3. (2001) "Product Information. Piperazine (piperazine)." Global Pharmaceutical Corporation
Moderate

Thiabendazole (applies to Mintezol) liver disease

Moderate Potential Hazard, Moderate plausibility.

Thiabendazole is extensively metabolized by the liver. Therapy with thiabendazole should be administered cautiously and with careful monitoring in patients with liver disease.

References

  1. Roy MA, Nugent FW, Aretz HT (1989) "Micronodular cirrhosis after thiabendazole." Dig Dis Sci, 34, p. 938-41
  2. Fink AI, MacKay CJ, Cutler SS (1979) "Sicca complex and cholangiostatic jaundice in two members of a family probably caused by thiabendazole." Ophthalmology, 86, p. 1892-6
  3. Tocco DJ, Rosenblum C, Martin CM, Robinson HJ (1966) "Absorption, metabolism, and excretion of thiabendazole in man and laboratory animals." Toxicol Appl Pharmacol, 9, p. 31-9
  4. (2001) "Product Information. Mintezol (thiabendazole)." Merck & Co., Inc
  5. Bion E, Pariente EA, Maitre F (1995) "Severe cholestasis and sicca syndrome after thiabendazole." J Hepatol, 23, p. 762-3
View all 5 references
Moderate

Thiabendazole (applies to Mintezol) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

Thiabendazole is excreted in the urine (90%). Therapy with thiabendazole should be administered cautiously and with careful monitoring in patients with renal dysfunction.

References

  1. Bauer LA, Raisys VA, Watts MT, Ballinger J (1982) "The pharmacokinetics of thiabendazole and its metabolites in an anephric patient undergoing hemodialysis and hemoperfusion." J Clin Pharmacol, 22, p. 276-80
  2. Schumaker JD, Band JD, Lensmeyer GL, Craig WA (1978) "Thiabendazole treatment of severe strongyloidiasis in a hemodialyzed patient." Ann Intern Med, 89, p. 644-5
  3. Leapman SB, Rosenberg JB, Filo RS, Smith EJ (1980) "Strongyloides stercoralis in chronic renal failure: safe therapy with thiabendazole." South Med J, 73, p. 1400-2
  4. Tocco DJ, Rosenblum C, Martin CM, Robinson HJ (1966) "Absorption, metabolism, and excretion of thiabendazole in man and laboratory animals." Toxicol Appl Pharmacol, 9, p. 31-9
  5. (2001) "Product Information. Mintezol (thiabendazole)." Merck & Co., Inc
View all 5 references

Mintezol drug interactions

There are 52 drug interactions with Mintezol (thiabendazole).

Mintezol alcohol/food interactions

There is 1 alcohol/food interaction with Mintezol (thiabendazole).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer